ROX-Heart index predicts successful weaning from high-flow oxygen therapy in patients with COVID-19 pneumonia at Thammasat University Hospital

Completed

• Conditions: COVID-19PneumoniaRespiratory failure; COVID-19; Pneumonia; Respiratory failure; Heart rate; Weaning; ROX index

• Registration Number: TCTR20221108004
• Lead Sponsor: Faculty of Medicine, Thammasat University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-08
• Study Completion: 2023-12-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 162

Inclusion Criteria

1. Age 18 years or more, 2. Confirmed COVID-19 pneumonia by RT-PCR test and chest radiographic imaging, 3. HFNC treatment within 24 hours after admission

Exclusion Criteria

1. No available daata, 2. Arrhythmia, 3. Treatment with beta-blocker, non-dihydropyridine calcium-channel blocker, amiodarone, or digoxin

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cutoff value of ROX-Heart index for predicting the successful weaning from HFNC At 2, 4, 5, 6, 7, 14 days Points

Secondary Outcome Measures

Name	Time	Method
Prevalence of successful weaning from HFNC At 2 weeks after HFNC use Percent